ALEC vs. CCCC, ITOS, NK, BDTX, RGNX, FUSN, INBX, SANA, NMRA, and DNA
Should you be buying Alector stock or one of its competitors? The main competitors of Alector include C4 Therapeutics (CCCC), iTeos Therapeutics (ITOS), NantKwest (NK), Black Diamond Therapeutics (BDTX), REGENXBIO (RGNX), Fusion Pharmaceuticals (FUSN), Inhibrx (INBX), Sana Biotechnology (SANA), Neumora Therapeutics (NMRA), and Ginkgo Bioworks (DNA). These companies are all part of the "medical" sector.
Alector (NASDAQ:ALEC) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.
Alector presently has a consensus target price of $14.00, indicating a potential upside of 184.55%. C4 Therapeutics has a consensus target price of $10.13, indicating a potential upside of 102.50%. Given Alector's stronger consensus rating and higher possible upside, equities analysts plainly believe Alector is more favorable than C4 Therapeutics.
In the previous week, Alector and Alector both had 3 articles in the media. Alector's average media sentiment score of 1.07 beat C4 Therapeutics' score of 0.94 indicating that Alector is being referred to more favorably in the media.
Alector has higher revenue and earnings than C4 Therapeutics. Alector is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.
Alector has a net margin of -125.11% compared to C4 Therapeutics' net margin of -629.24%. C4 Therapeutics' return on equity of -52.85% beat Alector's return on equity.
Alector has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, C4 Therapeutics has a beta of 3.22, indicating that its share price is 222% more volatile than the S&P 500.
85.8% of Alector shares are owned by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are owned by institutional investors. 9.1% of Alector shares are owned by insiders. Comparatively, 8.0% of C4 Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Alector received 121 more outperform votes than C4 Therapeutics when rated by MarketBeat users. Likewise, 60.58% of users gave Alector an outperform vote while only 37.88% of users gave C4 Therapeutics an outperform vote.
Summary
Alector beats C4 Therapeutics on 13 of the 17 factors compared between the two stocks.
Get Alector News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALEC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
